Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Authors:
Razzaki TS; Weiner A; Shukla AP.

Journal:
Ther Clin Risk Manag

Publication Year: 2022

DOI:
10.2147/TCRM.S328056

PMCID:
PMC9527616

PMID:
36199834

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Clin Risk Manag

Abbreviation: Ther Clin Risk Manag

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Health Care Sciences & Services

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physicia…
Bindra J; Chopra I; Hayes K and 3 more (2024) - Transparency Score: 3/6
Classification and Regression Tree Predictive Model for Acute Kidney Injury in Traumatic Brain Inju…
Wang R; Zhang J; He M and 1 more (2024) - Transparency Score: 3/6
Factors Influencing the Fasting Time in Adult Patients After the Endoscopic Management of Sharp Eso…
Wu DQ; Chen SY; Chen KG and 3 more (2024) - Transparency Score: 3/6
Profile of Sofosbuvir and Velpatasvir Combination in the Treatment of Chronic Hepatitis C in Childr…
Brigham D; Narkewicz MR. (2024) - Transparency Score: 2/6
Risk Factors of Chylothorax After Congenital Heart Surgery in Infants: A Single-Centre Retrospectiv…
Zhang RG; Liu YM; Yao ZY and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Razzaki is a medical advisor for Measured. Drs. Weiner and Shukla report no conflicts of interest in this work."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025